53 recruiting, 31 completed, 25 active not recruiting, 24 not yet recruiting. 102 Phase 2, 43 Phase 1, 28 Phase 3, 12 Not applicable, 3 Phase 4.
Follow blinatumomab: new trials by email Literature Review of blinatumomab trials Research Report on blinatumomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Asciminib, Biospecimen Collection, Blinatumomab - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 21 | 2027-10-13 | 2026-11-03 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-12-01 | 2026-11-09 |
| Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL Inotuzumab ozogamicin (INO), Venetoclax (VEN), Vincristine - ALL | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2026-11-30 | 2026-11-06 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-11-02 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-11-12 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2026-10-12 | 2026-09-25 |
| Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome Blinatumomab, background treatment - Primary Sjögren's Syndrome (pSS) | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 12 | 2026-09-25 | 2026-10-01 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Recruiting | Charite University, Berlin, Germany | 750 | 2026-09-01 | 2026-10-26 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 212 | 2026-08-09 | 2026-07-23 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-11-12 |
| Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage Blinatumomab, Venetoclax - Adult ALL, MPAL | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-06-30 | 2026-02-11 |
| Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis Blinatumomab - Autoimmune Encephalitis (AE), Autoimmune Cerebellitis | Phase 4 | Not yet recruiting | Beijing Tiantan Hospital | 12 | 2026-06-24 | 2026-07-06 |
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-12 | 2026-06-11 |
| ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL Olverembatinib, Gecacitinib, Venetoclax - Ph-Like, Acute Lymphoblastic Leukemia | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 92 | 2026-05-30 | 2026-05-13 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-11-10 |
| Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 26 | 2026-05-13 | 2026-10-16 |
| A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia BCL-2 indibitor, Azacitidine (AZA), Blinatumomab - Newly Diagnosed Mixed Phenotype Acute Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 52 | 2026-05-01 | 2026-05-07 |
Showing 20 of 165. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (74) · Burkitt Lymphoma (44) · Neoplasm, Residual (18) · Recurrence (17) · Leukemia (16) · Leukemia, Biphenotypic, Acute (9) · Lymphoma, Non-Hodgkin (8) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (7) · Lymphoproliferative Disorders (6) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Immunoproliferative Disorders (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Lymphoma (4) · Lymphoma, B-Cell (4)
Amgen (20) · M.D. Anderson Cancer Center (16) · Institute of Hematology & Blood Diseases Hospital, China (14) · National Cancer Institute (NCI) (11) · Amgen Research (Munich) GmbH (7) · The First Affiliated Hospital of Soochow University (7) · St. Jude Children's Research Hospital (6) · Goethe University (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · City of Hope Medical Center (3) · First Affiliated Hospital of Zhejiang University (3) · Sichuan University (3) · Assistance Publique - Hôpitaux de Paris (2) · Chen Suning (2) · MedImmune LLC (2)
United States (76) · China (33) · Germany (28) · France (25) · Italy (24) · Australia (19) · Spain (18) · Canada (16) · Austria (13) · Belgium (13) · Netherlands (13) · United Kingdom (13) · Israel (12) · Puerto Rico (10) · Czechia (9)
Elias Jabbour (5) · Elias Jabbour, MD (4) · Nicola Goekbuget, MD (4) · Brandon Triplett, MD (3) · Xiaofan Zhu, MD (3) · Elias J Jabbour, MD (2) · Max Topp, MD (2) · Suning Chen (2) · A.W. Rijneveld, Dr. (1) · Alessandro Rambaldi (1)
PMID 41671463, PMID 35622074, PMID 27209293, PMID 22592608, PMID 25192414, PMID 25385737, PMID 25524800, PMID 26755709, PMID 27873237, PMID 27998223, PMID 28533941, PMID 28859185, PMID 28922466, PMID 29352703, PMID 29358182, PMID 30254079, PMID 31648325, PMID 32289160, PMID 32546071, PMID 32589970, PMID 32619115, PMID 33085860, PMID 33191168, PMID 33542479, PMID 33651090, PMID 33844429, PMID 34161631, PMID 34228983, PMID 34914826, PMID 35129146, PMID 35501736, PMID 35503708, PMID 35713551, PMID 35941212, PMID 35982483, PMID 36000952, PMID 36279879, PMID 36322825, PMID 36402146, PMID 37131217, PMID 37141547, PMID 37187201, PMID 37257143, PMID 37871306, PMID 38127722, PMID 38135369, PMID 38551807, PMID 38841802, PMID 39028925, PMID 39047240
U10CA180886 (6), 2016 (5), 2025 (4), 2023 (3), 2014 (2), 2017 (2), P30CA033572 (2), U10CA180820 (2), U10CA180888 (2), 2015 (1), P30CA093373 (1), U10CA021115 (1), U10CA098543 (1), U10CA180821 (1), U24CA196172 (1)